| P2093 | author name string | Natasha T Snider | |
| | Paul F Hollenberg | |
| | Vyvyca J Walker | |
| P2860 | cites work | Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide | Q36611878 |
| | Cannabinoid CB2 receptor: a new target for controlling neural cell survival? | Q36671508 |
| | Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. | Q36692860 |
| | Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation | Q36698861 |
| | Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain | Q36727266 |
| | Biochemistry and pharmacology of endovanilloids | Q36756199 |
| | Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice | Q36800423 |
| | Expression and function of cytochrome p450 in brain drug metabolism | Q36822882 |
| | Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors | Q36861457 |
| | Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. | Q36863470 |
| | Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis | Q36891502 |
| | Characterization of orphan human cytochromes P450. | Q36929625 |
| | The soluble epoxide hydrolase as a pharmaceutical target for hypertension | Q36945495 |
| | Cannabinoids and neuroprotection in basal ganglia disorders. | Q36977766 |
| | Prospective teratology of retinoic acid metabolic blocking agents (RAMBAs) and loss of CYP26 activity | Q36990344 |
| | CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits | Q37012022 |
| | The brain as a target for inflammatory processes and neuroprotective strategies | Q37031200 |
| | Targeting the endocannabinoid system: to enhance or reduce? | Q37150745 |
| | Biosynthesis, degradation and pharmacological importance of the fatty acid amides | Q37155833 |
| | Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. | Q37160635 |
| | The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependent | Q21092130 |
| | Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11 | Q22011198 |
| | Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism | Q24310355 |
| | Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart | Q24311574 |
| | cDNA cloning and characterization of human and mouse Ca(2+)-independent phosphatidylethanolamine N-acyltransferases | Q24313273 |
| | A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure | Q24317533 |
| | Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11 | Q24322910 |
| | CB2 receptor-mediated migration of immune cells: it can go either way | Q24643591 |
| | CB2 receptors in the brain: role in central immune function | Q24643895 |
| | The endocannabinoid system as an emerging target of pharmacotherapy | Q24648473 |
| | The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration | Q24651712 |
| | Arachidonic acid cytochrome P450 epoxygenase pathway | Q24653023 |
| | Identification of intracellular carriers for the endocannabinoid anandamide | Q24658373 |
| | A biosynthetic pathway for anandamide | Q24671032 |
| | LMSD: LIPID MAPS structure database | Q24675592 |
| | Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids | Q24680497 |
| | Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain | Q27655121 |
| | Molecular characterization of a phospholipase D generating anandamide and its congeners | Q28186509 |
| | Clinical importance of the cytochromes P450 | Q28208454 |
| | Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 |
| | Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles | Q28244409 |
| | Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation | Q28244417 |
| | Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins | Q28246834 |
| | Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism | Q28252850 |
| | Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor | Q28269433 |
| | Identification of a high-affinity binding site involved in the transport of endocannabinoids | Q28284073 |
| | Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 |
| | Metabolism of vitamin D3 by cytochromes P450 | Q28296000 |
| | Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 |
| | Arachidonic acid as a bioactive molecule | Q28366329 |
| | Soluble epoxide hydrolase: a novel therapeutic target in stroke | Q28388145 |
| | Steroidogenic enzymes | Q37168925 |
| | Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. | Q37197332 |
| | The future of endocannabinoid-oriented clinical research after CB1 antagonists. | Q37226111 |
| | Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology | Q37261843 |
| | Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain | Q37312874 |
| | Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation | Q37382150 |
| | The role of the endocannabinoid system in liver diseases | Q37414553 |
| | Enzymatic formation of anandamide | Q37568597 |
| | Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals | Q38289917 |
| | Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. | Q38301638 |
| | New tetrazole-based selective anandamide uptake inhibitors | Q39990515 |
| | Multiple pathways involved in the biosynthesis of anandamide | Q40106992 |
| | Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets | Q40184192 |
| | CYP4A11 is repressed by retinoic acid in human liver cells | Q40277767 |
| | Characterization of transgenic mice with neuron-specific expression of soluble epoxide hydrolase | Q40383476 |
| | A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. | Q40528853 |
| | Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides | Q40702429 |
| | Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. | Q41093128 |
| | Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway | Q41791622 |
| | A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist | Q42017075 |
| | Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain | Q42248322 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor | Q43644239 |
| | Progesterone oxidation by cytochrome P450 2D isoforms in the brain | Q43715823 |
| | Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor | Q43803513 |
| | Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study | Q44087253 |
| | Chronic treatment with the endocannabinoid anandamide increases cytochrome P450 metabolizing system in the rat. | Q44090384 |
| | Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 |
| | Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels | Q44524443 |
| | Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity | Q44903331 |
| | A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes | Q45000502 |
| | Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia | Q45149383 |
| | CYP2D in the brain | Q45201297 |
| | Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. | Q46054832 |
| | Microsomal cytochrome P450-mediated liver and brain anandamide metabolism | Q46201966 |
| | Antifibrogenic role of the cannabinoid receptor CB2 in the liver | Q46376137 |
| | Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa | Q46446318 |
| | Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers | Q46504854 |
| | Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism | Q46520416 |
| | Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis | Q46533142 |
| | RNA interference-mediated knockdown of dynamin 2 reduces endocannabinoid uptake into neuronal dCAD cells | Q46626825 |
| | Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. | Q46639969 |
| | Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice | Q46652514 |
| | Effects of selective inhibition of cytochrome P-450 omega-hydroxylases and ischemic preconditioning in myocardial protection | Q46743934 |
| | The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells | Q46875092 |
| | Fatty acid amide hydrolase determines anandamide-induced cell death in the liver | Q46897847 |
| | Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids | Q46939863 |
| | Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. | Q48028956 |
| | Testosterone metabolism in rat brain is differentially enhanced by phenytoin-inducible cytochrome P450 isoforms | Q48136337 |
| | Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. | Q48232884 |
| | Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease | Q48247414 |
| | Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats | Q48302618 |
| | Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain | Q48360198 |
| | Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. | Q50890840 |
| | Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. | Q51819821 |
| | The quantification of cytochrome P-450 (CYP 3A4) mRNA in the blood of patients with viral liver diseases. | Q54664300 |
| | Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type | Q54692647 |
| | Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction | Q57315163 |
| | Cytochrome P -450 activities in human and rat brain microsomes | Q57550376 |
| | Relationship between personality and debrisoquine hydroxylation capacity | Q57586041 |
| | Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain | Q60679661 |
| | Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells | Q61479730 |
| | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. | Q64937528 |
| | Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease | Q67516972 |
| | Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes | Q71216118 |
| | Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides | Q79711201 |
| | Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease | Q79802329 |
| | Expression, activity and regulation of CYP3A in human and rodent brain | Q80660179 |
| | CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis | Q83820609 |
| | Cytochrome P450 2D Catalyze Steroid 21-Hydroxylation in the Brain | Q28568335 |
| | Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia | Q28570530 |
| | The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands | Q28578924 |
| | Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D | Q28581971 |
| | Microglia: active sensor and versatile effector cells in the normal and pathologic brain | Q29547240 |
| | Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 |
| | Modulation of anxiety through blockade of anandamide hydrolysis | Q29615902 |
| | Cannabinoid receptor signaling. | Q30353713 |
| | Predicting in vivo drug interactions from in vitro drug discovery data | Q31011412 |
| | Molecular cloning and regulation of expression of two novel mouse CYP4F genes: expression in peroxisome proliferator-activated receptor alpha-deficient mice upon lipopolysaccharide and clofibrate challenges | Q31842794 |
| | Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis | Q33464957 |
| | Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells | Q33687100 |
| | Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. | Q33845285 |
| | Promoter activity and regulation of the CYP4F2 leukotriene B(4) omega-hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells | Q33906310 |
| | Molecular analysis of patient and carrier genes with congenital steroid 21-hydroxylase deficiency by using polymerase chain reaction and single strand conformation polymorphism | Q33907184 |
| | Regulation of CYP4F2 leukotriene B4 omega-hydroxylase by retinoic acids in HepG2 cells | Q33931951 |
| | Transgenic mouse models of human CYP3A4 gene regulation | Q33966651 |
| | N-Acylation of ethanolamine phospholipids in canine myocardium | Q34056987 |
| | A historical overview of chemical research on cannabinoids | Q34098950 |
| | The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase | Q34116662 |
| | Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. | Q34152279 |
| | Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. | Q34331552 |
| | Gene conversion-like events cause steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia | Q34366737 |
| | Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. | Q34397288 |
| | Anandamide transport: a critical review. | Q34429012 |
| | Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases | Q34442004 |
| | Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system | Q34463893 |
| | A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo | Q34467166 |
| | The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases | Q34550883 |
| | Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial | Q34567633 |
| | Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine | Q34582005 |
| | Nabilone for the treatment of pain in fibromyalgia | Q34584429 |
| | LIPID MAPS online tools for lipid research | Q34640464 |
| | Prostamides (prostaglandin-ethanolamides) and their pharmacology | Q34667670 |
| | Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects | Q34713638 |
| | Cannabinoid receptors: where they are and what they do. | Q34772274 |
| | The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure | Q34788462 |
| | The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. | Q34807695 |
| | A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men. | Q34908413 |
| | Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. | Q34997982 |
| | Inhibitors of cytochrome P450 4A suppress angiogenic responses | Q35083648 |
| | Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry | Q35584152 |
| | Oxidative metabolism of endocannabinoids by COX-2. | Q35668355 |
| | Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils | Q35723681 |
| | Cytochrome P450 in neurological disease | Q35793932 |
| | The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. | Q35828032 |
| | Mitogenic activity and signaling mechanism of 2-(14,15- epoxyeicosatrienoyl)glycerol, a novel cytochrome p450 arachidonate metabolite | Q35856833 |
| | Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity | Q35922156 |
| | Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease | Q35981986 |
| | Cytochrome P450: nature's most versatile biological catalyst | Q36098993 |
| | Endocannabinoid control of food intake and energy balance | Q36108722 |
| | Structure and function of fatty acid amide hydrolase | Q36161171 |
| | Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases | Q36178387 |
| | Anandamide as an intracellular messenger regulating ion channel activity | Q36228963 |
| | Neuroinflammation: a potential therapeutic target | Q36268282 |
| | Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. | Q36320257 |
| | Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase | Q36403694 |
| | Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury | Q36431793 |
| | Pharmacological actions of cannabinoids. | Q36441175 |
| | Distribution of cannabinoid receptors in the central and peripheral nervous system. | Q36441196 |
| | Human studies of cannabinoids and medicinal cannabis. | Q36441235 |
| | Cannabinoids biology: the search for new therapeutic targets | Q36523618 |
| | Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). | Q36533477 |
| | Mitochondrial P450s | Q36555033 |
| | Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism | Q36574121 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoids | Q422936 |
| P304 | page(s) | 136-154 | |
| P577 | publication date | 2010-02-04 | |
| P1433 | published in | Pharmacological Reviews | Q2085079 |
| P1476 | title | Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications | |
| P478 | volume | 62 | |